Introduction {#S1}
============

Recognition of a pathogen by the immune system initiates a multi-step transcriptional program which directs CD4^+^ T cell differentiation into distinct T helper populations (T~H~) that coordinate eradication of infection. T~H~1 effector cells secrete inflammatory cytokines and activate immune cells^[@R1]^. Follicular helper (T~FH~) cells secrete cytokines and upregulate ligands that induce B cells to form germinal centers, class switch, and generate high-affinity antibodies^[@R2]^. Differentiation of CD4^+^ T cells is directed by cytokine-induced activation of STAT proteins and lineage determining transcription factors such as T-bet and Bcl6^[@R3]^. Following activation, T~H~1 cells receive signals that initiate T-bet expression and induce migration from the lymphoid tissues to infected or inflamed areas of the body^[@R1]^. In contrast, to properly differentiate, T~FH~ cells must upregulate Bcl6 and the chemokine receptor CXCR5 allowing movement from the T cell zone into the B cell follicle^[@R2]^. The differentiation of T~H~1 and T~FH~ cells is interconnected through antagonistic interplay between T-bet and Bcl6, and Bcl6 and Blimp-1^[@R4]--[@R8]^.

E protein transcription factors and their natural repressors, the inhibitor of DNA binding (Id) proteins, play a crucial role in the differentiation of numerous lymphocyte populations such as B cells, innate lymphoid cells, natural killer cells, invariant NKT cells, αβ γδ and CD8^+^ effector and memory T cells^[@R9]--[@R17]^. Recently, studies have highlighted the role played by Id2, Id3 and E proteins in mature CD4^+^ T cells, particularly in the differentiation and maintenance of regulatory T (T~reg~) cells and T~H~17 cells^[@R18]--[@R21]^. Deletion of E proteins leads to an increase in T~reg~ cell populations; however, deletion of Id2 and Id3 cripples the differentiation and localization of Foxp3^+^ T~reg~ cells^[@R18],[@R20]^. Additionally, Id2-deficient CD4^+^ T cells were unable to mount a robust T~H~17 response in a mouse model of experimental autoimmune encephalomyelitis^[@R21]^. Ectopically expressed basic helix-loop-helix (bHLH) transcription factor achaete-scute homolog 2 (Ascl2) binds E-box sites to drive upregulation of CXCR5 *in vitro*, resulting in augmented accumulation of CD4^+^ T cells in the B cell follicle *in vivo*^[@R22]^. However, Ascl2 did not induce Bcl6, raising the question of how E protein activity and the induction of CXCR5 and Bcl6 are interrelated. Furthermore, our own studies have shown differential Id2 and Id3 mRNA expression in T~H~1 and T~FH~ cells^[@R23]^. Thus, we further explored the biology of Id2 and Id3 in the differentiation of T~H~1 and T~FH~ during infection.

Results {#S2}
=======

Id2 and Id3 define T~H~1 and T~FH~ effector CD4^+^ T cell subsets {#S3}
-----------------------------------------------------------------

We determined the abundance of Id2 and Id3 in CD4^+^ T cell subsets by using reporter mice in which cDNA encoding for yellow fluorescent protein (YFP) or green fluorescent protein (GFP) were inserted in the *Id2*^[@R14]^ or *Id3*^[@R24]^ gene, respectively. We crossed both lines to SMARTA TCR transgenic mice (LCMV-specific, gp66-77 IA^b^-restricted) to generate *Id2*^YFP/+^ and *Id3*^GFP/+^ SMARTA CD4^+^ T cells, which were transferred into B6 hosts that were then infected with LCMV-Armstrong. T~H~1 and T~FH~ differentiation was assessed in Id2-YFP^lo^ and Id2-YFP^hi^ subsets following infection. In parallel, we infected *Id2*^YFP/+^ or *Id3*^GFP/+^ mice with LCMV to follow polyclonal CD4^+^ T cell differentiation. We observed that Id2-YFP^lo^ cells were almost exclusively T~FH~ cells (CXCR5^+^SLAM^lo^ or CXCR5^+^PD-1^lo^) and GC T~FH~ (CXCR5^+^PD-1^+^), while the vast majority of Id2-YFP^hi^ cells displayed a T~H~1 phenotype (SLAM^+^CXCR5^−^ or CXCR5^−^PD-1^−^) ([Fig. 1a](#F1){ref-type="fig"}, [Supplementary Fig. 1a](#SD1){ref-type="supplementary-material"}). Similarly, we found that Id3 expression was highly polarized: Id3-GFP^lo^ cells enriched in the T~H~1 population and Id3-GFP^hi^ cells enriched in T~FH~ and GC T~FH~ populations ([Fig. 1b](#F1){ref-type="fig"}, [Supplementary Fig. 1b](#SD1){ref-type="supplementary-material"}).

We also generated *Id2*^YFP/+^*Id3*^GFP/+^ dual reporter mice and analyzed coordinate Id2 and Id3 expression after LCMV infection. Naive CD4^+^ T cells expressed intermediate and high amounts of Id2 and Id3, respectively. After infection, T~H~1 cells showed a substantial increase in Id2-YFP expression compared to naive cells ([Fig. 1c](#F1){ref-type="fig"}). In contrast, T~H~1 cells lost Id3-GFP expression, and T~FH~ cells maintained high expression of Id3-GFP ([Fig. 1c](#F1){ref-type="fig"}). Compared to T~FH~ cells, GC T~FH~ cells had equivalent expression of Id3-GFP reporter (data not shown). Histology revealed that the majority of Id2-YFP expressing CD4^+^ T cells were excluded from the B cell follicle and germinal center ([Fig. 1d](#F1){ref-type="fig"}). Our results show that Id2 and Id3 have contrasting expression patterns in T~H~1 and T~FH~ cells following acute LCMV infection.

Impaired *Id2* expression enhances T~FH~ differentiation {#S4}
--------------------------------------------------------

To determine if differential *Id2* expression in CD4^+^ T cells influences CD4^+^ T cell differentiation *in vivo*, we expressed an shRNAmir specific for *Id2* (sh*Id2*) or a control shRNAmir (shCtrl) in SMARTA CD4^+^ T cells, transferred cells into B6 mice, and analyzed T cell differentiation after LCMV infection. Expression of sh*Id2* in SMARTA CD4^+^ T cells reduced *Id2* mRNA expression ([Supplementary Fig. 2a](#SD1){ref-type="supplementary-material"}). Among sh*Id2*^+^ cells, there was an increased frequency of T~FH~ cells and decreased frequency of T~H~1 cells compared to shCtrl ([Fig. 2a--c](#F2){ref-type="fig"}). The bias was predominantly attributed to GC T~FH~ cells, identified as CXCR5^+^Bcl6^+^ cells ([Fig. 2d--f](#F2){ref-type="fig"}) or CXCR5^+^PSGL-1^lo^ ([Supplementary Fig. 2c--e](#SD1){ref-type="supplementary-material"}). We then examined the differentiation of sh*Id2*^+^ cells earlier after infection ([Supplementary Fig. 2f](#SD1){ref-type="supplementary-material"}) and observed an increased frequency of CXCR5^+^Bcl6^+^ T~FH~ and a decreased T~H~1 (CXCR5^−^ Bcl6^−^) population among sh*Id2*^+^ cells ([Fig. 2g--i](#F2){ref-type="fig"}). Analysis of early T~FH~ cells (CXCR5^+^CD25^−^)^[@R25],[@R26]^ also revealed an increased proportion among sh*Id2*^+^ cells ([Supplementary Fig. 2g--i](#SD1){ref-type="supplementary-material"}). Thus, impaired Id2 expression appears to favor T~FH~ differentiation.

To examine B cell help by sh*Id2*^+^ CD4^+^ T cells we transferred sh*Id2*^+^ or shCtrl^+^ OT-II CD4^+^ cells into *Bcl6*^fl/fl^ CD4-Cre^+^ mice^[@R27]^, followed by immunization with NP-OVA in alum. After immunization, more sh*Id2*^+^ T cells had differentiated into CXCR5^+^PD-1^+^ or CXCR5^+^Bcl6^+^ GC T~FH~ than control cells ([Supplementary Fig. 2j,k](#SD1){ref-type="supplementary-material"}). Increased frequencies of GC B cells ([Fig. 2k](#F2){ref-type="fig"}) and plasma cells ([Fig. 2l](#F2){ref-type="fig"}) were observed in sh*Id2*^+^ recipients compared to control, with no differences in the NP-specific IgG titers ([Fig. 2m](#F2){ref-type="fig"}), despite slightly reduced accumulation of sh*Id2*^+^ CD4^+^ T cells ([Fig. 2j](#F2){ref-type="fig"}). Thus, Id2 expression appears to negatively impact T~FH~ cell differentiation.

Id2 is necessary for generation of T~H~1 cells during infection {#S5}
---------------------------------------------------------------

We next asked how the total absence of Id2 affects CD4^+^ T cell differentiation. We crossed *Id2*-floxed (*Id2*^fl/fl^) mice^[@R28]^ to SMARTA TCR- and CD4-Cre transgenic lines to generate *Id2*^fl/fl^CD4-Cre^+^ SMARTA (*Id2*^−/−^) mice in which *Id2* is deleted in αβ thymocytes. Naive *Id2*^−/−^ SMARTA cells were CD44^low^ and indistinguishable from *Id2*^+/+^ cells (data not shown). We transferred naive *Id2*^+/+^ CD4-Cre^+^ SMARTA (*Id2*^+/+^) or *Id2*^−/−^ cells into B6 hosts and followed their differentiation after infection. *Id2*^−/−^ cells did not form a distinct T~H~1 population ([Fig. 3a,b](#F3){ref-type="fig"}, [Supplementary Fig. 3a](#SD1){ref-type="supplementary-material"}). Loss of T~H~1 differentiation by *Id2*^−/−^ cells was accompanied by decreased granzyme B, T-bet and IFNγ expression, and increased TCF-1 expression ([Supplementary Fig. 3b,c](#SD1){ref-type="supplementary-material"}). Notably, a prominent SLAM^mid^CXCR5^mid^ population emerged among *Id2*^−/−^ effector CD4^+^ T cells, which was not observed in *Id2*^+/+^ cells ([Fig. 3a,b](#F3){ref-type="fig"}). This phenotype was also apparent in a polyclonal CD4^+^ T cell response ([Supplementary Fig. 3d](#SD1){ref-type="supplementary-material"}). These results show that *Id2* is required for differentiation of T~H~1 cells.

To understand the dysregulation of *Id2*^−/−^ T~H~1 cells, we further characterized the phenotypes of the *Id2*^−/−^ populations after LCMV infection. *Id2*^+/+^ and *Id2*^−/−^ T~H~1 cells maintained high expression of PSGL-1 and IL-2Rα, which both need to be downregulated for proper T~FH~ differentiation^[@R25],[@R29]--[@R31]^ ([Fig. 3c,d](#F3){ref-type="fig"}). Analysis of the SLAM^mid^CXCR5^mid^ population revealed that *Id2*^−/−^ cells shared a partial phenotype with T~H~1 cells, including high expression of PSGL-1, Ly6C and IL-2Rα, and were Bcl6^low^ when compared to *Id2*^+/+^ or *Id2*^−/−^ T~FH~ cells ([Fig. 3c,d](#F3){ref-type="fig"}). Bcl6 expression was normal in sh*Id2*^+^ early T~H~1 and T~FH~ ([Supplementary Fig. 3e](#SD1){ref-type="supplementary-material"}) suggesting that partial loss of *Id2* does not impact T~H~1 cell phenotype. In contrast, the complete absence of *Id2* impacted CD4^+^ T cells throughout differentiation, permanently disrupting T~H~1 cells.

*Id2*^−/−^ cells were then assessed for their ability to support B cell responses. Eight days after LCMV infection of *Bcl6*^fl/fl^ CD4-Cre^+^ mice that had received *Id2*^+/+^ or *Id2*^−/−^ cells, we observed an increased frequency of *Id2*^−/−^ T~FH~ cells, but their numbers were similar ([Supplementary Fig. 3f](#SD1){ref-type="supplementary-material"}). Plasma cell frequencies and anti-LCMV IgG titers in the serum were unchanged ([Fig. 3e,f](#F3){ref-type="fig"}). However, GC B cell development was impaired in mice that received *Id2*^−/−^ cells ([Fig. 3e](#F3){ref-type="fig"}), suggesting that *Id2*^−/−^ T~FH~ cells may have impaired function.

To further characterize the differentiation status of *Id2*^−/−^ CD4^+^ T cells outside the limitations imposed by 2-parameter flow cytometric plots, and because many of the *Id2*^−/−^ cells could not be unambiguously assigned to either T~H~1 or T~FH~ based on SLAM or CXCR5 expression**,** we employed viSNE multi-parameter clustering, where the overall position of each cell reflects similarity to neighboring cells or dissimilarity to non-neighboring cells based on expression of CD4, CD45.1, SLAM, CXCR5, Bcl6, TCF-1, PD-1 and T-bet^[@R32]^. We observed two geographically distinct populations in total CD4^+^ or specifically in SMARTA CD4^+^ T cells that uniquely expressed the T~H~1 and T~FH~ markers SLAM and Bcl6, respectively ([Fig. 3g](#F3){ref-type="fig"}). *Id2*^+/+^ and *Id2*^−/−^ T~FH~ populations are similar in location and appearance ([Fig. 3g](#F3){ref-type="fig"}). However, *Id2*^−/−^ T~H~1 cells were located outside of the T~H~1 multiparameter gate defined by *Id2*^+/+^ T~H~1 cells ([Fig. 3g](#F3){ref-type="fig"}), further suggesting that Id2 is required for proper T~H~1 differentiation.

To examine the defect of T~H~1 differentiation in Id2-deficient cells, we employed a model of *Toxoplasma gondii* (*T. gondii)* infection for which the role of IFNγ-mediated T~H~1 responses for long-term resistance and control of infection is well established^[@R33]^. *Id2*^fl/fl^ CD4-Cre^+^ mice infected with *T. gondii* harbored CD4^+^ T cells with markedly reduced expression of both IFNγ and T-bet in the lamina propria of the small intestine compared to *Id2*^+/+^ CD4-Cre^+^ controls ([Fig. 3h](#F3){ref-type="fig"}). No significant alteration in the frequencies of Foxp3^+^ T~reg~ cells could be detected ([Fig. 3h](#F3){ref-type="fig"}). Thus in two distinct infections, we observe a severe loss of T~H~1 effector T cells.

Id3 restrains T~FH~ differentiation {#S6}
-----------------------------------

A second inhibitor of E protein activity, Id3, is chiefly expressed by T~FH~ and GC T~FH~ cells following infection and has been implicated as an inhibitor of T~FH~ differentiation. However, the role for Id3 in the generation of T~FH~ cells was not examined in the context of infection^[@R22]^. Thus, we generated *Id3*-floxed^[@R34]^ CD4-Cre^+^ SMARTA transgenic mice (*Id3*^−/−^), transferred cells into B6 mice, and infected with LCMV. In response to infection, *Id3*^−/−^ cells displayed an increased propensity to become both T~FH~ and GC T~FH~ when compared to *Id3*^+/+^ cells ([Supplementary Fig. 4a](#SD1){ref-type="supplementary-material"}). Further, an increase in frequency of GC T~FH~ was also observed in polyclonal Id3-deficient CD4^+^ T cells ([Supplementary Fig. 4b](#SD1){ref-type="supplementary-material"}). We next investigated whether constitutive expression of Id3 could inhibit T~FH~ differentiation; Id3-RV^+^ or GFP-RV^+^ LCMV NP-specific (NIP) CD4^+^ T cells^[@R35]^ were transferred into B6 mice, which were infected with LCMV. The acquisition of both T~FH~ ([Supplementary Fig. 4c](#SD1){ref-type="supplementary-material"}) and early T~FH~ ([Supplementary Fig. 4d](#SD1){ref-type="supplementary-material"}) characteristics were abrogated when Id3 was overexpressed. This is consistent with the observation that Id3 inhibited T~FH~ differentiation following protein immunization^[@R22]^.

Loss of Id2 regulates expression of key T~H~ genes {#S7}
--------------------------------------------------

To understand how Id2 impacts T~H~1 and T~FH~ cell differentiation, we studied the global transcriptional changes in CD4^+^ T cells resulting from *Id2* deficiency. *Id2*^+/+^ and *Id2*^−/−^ (encompassing both SLAM^hi^CXCR5^−^ and SLAM^mid^CXCR5^mid^ populations) T~H~1 and *Id2*^+/+^ and *Id2*^−/−^ CXCR5^+^SLAM^lo^ T~FH~ cells were used for comparative gene expression profiling ([Fig. 4a](#F4){ref-type="fig"}). Differential expression of T~H~1- and T~FH~-associated genes was confirmed for *Id2*^+/+^ T~H~1 and T~FH~ cells ([Fig. 4b](#F4){ref-type="fig"}). We then compared gene expression profiles of *Id2*^+/+^ and *Id2*^−/−^ T~H~1 cells and observed downregulation of T~H~1-associated genes (*Gzmb*, *Slamf1* and *Cxcr6)* in the context of *Id2* deficiency, while genes associated with the T~FH~ program (*Cxcr5*, *Il6ra* and *Tcf7*) were upregulated ([Fig. 4c](#F4){ref-type="fig"}). However, *Bcl6, Ascl2, Pdcd1* and *Icos*, all highly expressed by T~FH~ cells and important in T~FH~ differentiation, were not elevated in the *Id2*^−/−^ T~H~1 population when compared to *Id2*^+/+^ T~H~1 cells, indicating that E proteins control the expression of only a portion of T~FH~ signature genes ([Fig. 4d](#F4){ref-type="fig"}).

We next characterized the impact of *Id2* deficiency on the expression of T~H~1-associated genes. A T~H~1 gene set was selected as all genes upregulated ≥1.4 fold in *Id2*^+/+^ T~H~1 cells compared to *Id2*^+/+^ T~FH~ cells ([Fig. 4b](#F4){ref-type="fig"}, green). *Id2*^−/−^ T~H~1 cells had reduced expression for \~78% of the T~H~1-associated genes ([Fig. 4e](#F4){ref-type="fig"}). Additionally, of the 144 genes most substantially downregulated in *Id2*^−/−^ T~H~1 cells compared to *Id2*^+/+^ T~H~1 cells ([Fig. 4c](#F4){ref-type="fig"}, purple), \~79% were expressed at higher levels in *Id2*^+/+^ T~H~1 compared to *Id2*^+/+^ T~FH~ cells ([Fig. 4f](#F4){ref-type="fig"}). Thus, deletion of *Id2* impaired acquisition of the T~H~1 program.

A T~FH~ gene set was defined as all genes expressed ≥1.4 fold in *Id2*^+/+^ T~FH~ cells compared to *Id2*^+/+^ T~H~1 cells ([Fig. 4b](#F4){ref-type="fig"}, blue). *Id2*^−/−^ T~H~1 cells inappropriately upregulate \~69% of the T~FH~-associated genes ([Fig. 4g](#F4){ref-type="fig"}). Analysis of genes most upregulated in *Id2*^−/−^ T~H~1 cells compared to *Id2*^+/+^ T~H~1 cells ([Fig. 4c](#F4){ref-type="fig"}, grey) revealed that \~65% were preferentially expressed in *Id2*^+/+^ T~FH~ cells ([Fig. 4h](#F4){ref-type="fig"}). These analyses indicate a substantial bias towards the T~FH~ gene expression program in *Id2*^−/−^ T~H~1 cells. When gene expression of *Id2*^+/+^ and *Id2*^−/−^ T~FH~ cells was contrasted, only 140 genes showed significant differential expression, indicating that established T~FH~ cells, which express lower levels of *Id2*, were moderately impacted by *Id2* deficiency ([Fig. 4i](#F4){ref-type="fig"}).

The absence of proper T~H~1 development in *Id2*^−/−^ cells suggests that unchecked E2A activity impaired T~H~1 differentiation. Analysis of genes differentially expressed between *Id2*^+/+^ T~H~1 and T~FH~ cells revealed a larger number of E2A-bound genes were upregulated in *Id2*^−/−^ T~H~1 cells compared to *Id2*^+/+^ T~H~1 cells ([Fig. 4d](#F4){ref-type="fig"}), consistent with Id2 inhibition of E2A. We compared changes in gene expression with a list of E2A-target genes^[@R16]^ and found that 62% of the genes upregulated in *Id2*^−/−^ T~H~1 cells are targets of E2A ([Fig. 4j](#F4){ref-type="fig"}). These results suggest that Id2 is important for the maintenance of T~H~1 gene-expression program and that its absence results in acquisition of a partial T~FH~ program.

E proteins drive CXCR5 expression {#S8}
---------------------------------

Our microarray results suggest that Id2 and E proteins act together to control CD4^+^ T cell differentiation in part by regulating CXCR5 and expression of T~H~1 effector molecules such as SLAM. We hypothesized that diminished E2A levels could rescue the defect observed in *Id2*-deficient cells. We expressed an shRNA targeting *Tcf3* (encoding E2A) or a control shRNA in *Id2*^+/+^ and *Id2*^−/−^ SMARTA CD4^+^ T cells ([Supplementary Fig. 5a](#SD1){ref-type="supplementary-material"}). Cells were adoptively transferred into B6 mice infected the previous day, and differentiation of the transferred cells was analyzed. As expected, *Id2*^−/−^ cells expressing control shRNA could not correctly differentiate into T~H~1 cells ([Fig. 5a](#F5){ref-type="fig"}). However, *Id2*^−/−^ T~H~1 cells were rescued by sh*Tcf3* expression and defects in SLAM and CXCR5 expression were both corrected ([Fig. 5a](#F5){ref-type="fig"}). Thus, the defective T~H~1 differentiation we observe in the absence of Id2 is the result of increased E protein activity.

The E-box binding bHLH transcription factor Ascl2 has been shown to drive robust T~FH~ differentiation by inducing CXCR5 when overexpressed in CD4^+^ T cells^[@R22]^. E proteins *Tcf3* and *Tcf12* (HEB) are both highly expressed in T~FH~ cells early after LCMV infection ([Supplementary Fig. 5b](#SD1){ref-type="supplementary-material"})^[@R26]^. In contrast, *Ascl2* is essentially undetectable in either T~FH~ or T~H~1 cells at the same time point ([Supplementary Fig. 5b](#SD1){ref-type="supplementary-material"}). Retroviruses overexpressing the *Tcf3* isoforms E12, E47 or Ascl2 all induced CXCR5 expression by CD4^+^ T cells *in vitro* ([Fig. 5b](#F5){ref-type="fig"}). Ectopic expression of E47 led to enhanced expression of CXCR5 by both early T~H~1 cells and early T~FH~ cells when compared to their GFP-RV^+^ counterparts *in vivo* ([Fig. 5c](#F5){ref-type="fig"}, [Supplementary Fig. 5c](#SD1){ref-type="supplementary-material"}).

Given that Id2 inhibits the transcriptional activity of E proteins and E proteins induce CXCR5 expression, we investigated whether Id2 inhibited T~FH~ differentiation by preventing expression of CXCR5. *Id2*-RV^+^ or GFP-RV^+^ NIP CD4^+^ T cells were transferred into B6 mice, which were infected with LCMV. *Id2*-RV^+^ NIP CD4^+^ T cells displayed decreased differentiation into early T~FH~ cells ([Fig. 5d,f,g](#F5){ref-type="fig"}) and impaired CXCR5 expression ([Fig. 5e](#F5){ref-type="fig"}, [Supplementary Fig. 5e](#SD1){ref-type="supplementary-material"}). Overexpression of *Id2* did not impact expression of T-bet or accumulation of *Id2*-RV^+^ NIP CD4^+^ T cells ([Supplementary Fig. 5d,f](#SD1){ref-type="supplementary-material"}). Similar to what was previously observed, *Id2*-RV^+^ NIP CD4^+^ T cells poorly differentiated into T~FH~ cells 6 days after LCMV infection ([Fig. 5h,j,k](#F5){ref-type="fig"}, [Supplementary Fig. 5g--j](#SD1){ref-type="supplementary-material"}), with impaired CXCR5 expression by T~FH~ cells ([Fig. 5i](#F5){ref-type="fig"}, [Supplementary Fig. 5k](#SD1){ref-type="supplementary-material"}). Additionally, accumulation of *Id2*-RV^+^ GC T~FH~ cells was impaired ([Fig. 5h,j,k](#F5){ref-type="fig"}). Next, we constitutively co-expressed E proteins, Ascl2 and Id2 in CD4^+^ T cells. E proteins were expressed from a GFP reporter RV while Id2 was expressed from an Ametrine reporter RV. As expected, the E proteins E12, E47 and Ascl2 drove strong CXCR5 expression when CD4^+^ T cells were co-transduced with an empty Ametrine-RV ([Fig. 5l](#F5){ref-type="fig"}). When Id2-Ame-RV was introduced into E12- or E47-RV^+^ CD4^+^ T cells, there was a reduction in CXCR5 expression ([Fig 5l](#F5){ref-type="fig"}) by GFP^+^Ametrine^+^ cells. Surprisingly, Id2 was not able to block the Ascl2-driven induction of CXCR5 ([Fig. 5l](#F5){ref-type="fig"}). These data indicate that Id2 prevents E proteins from inducing CXCR5 expression.

Bcl6 inhibits *Id2* expression {#S9}
------------------------------

Our data show that the Id2-E protein axis modulates T~H~1 and T~FH~ differentiation, and that Id2 inhibits expression of *Cxcr5*. The transcriptional repressor Bcl6 is essential for T~FH~ differentiation and is important for CXCR5 expression by T~FH~ cells *in vivo*^[@R8],[@R25],[@R36]^, but it does not directly regulate *Cxcr5*^[@R22],[@R37]^. We therefore asked whether Bcl6 induces CXCR5 expression by inhibiting *Id2* transcription. Bcl6 ChIP-Seq of primary tonsillar GC T~FH~ revealed recruitment of BCL6 to the *ID2* locus ([Fig. 6a](#F6){ref-type="fig"})^[@R37]^, which was confirmed by ChIP-qPCR ([Fig. 6b](#F6){ref-type="fig"}). To test whether Bcl6 represses *Id2* expression, we transduced *Bcl6*^fl/fl^ CD4-Cre^+^ SMARTA CD4^+^ T cells (*Bcl6*^−/−^) with GFP-RV or Bcl6-RV, transferred RV^+^ cells into B6 mice, infected with LCMV, and assessed expression of *Id2* ([Supplementary Fig. 6a](#SD1){ref-type="supplementary-material"}, [Fig. 6c](#F6){ref-type="fig"}). Re-introduction of Bcl6 into *Bcl6*^−/−^ cells led to significant repression of *Id2* in IL-2Rα^hi^ Th1 cells ([Fig. 6c](#F6){ref-type="fig"}). Recent work demonstrated that separate domains of Bcl6 control T~FH~ differentiation, and mutation of lysine K379Q significantly hinders the activity of Bcl6^[@R27],[@R35]^. Introduction of the Bcl6 K379Q mutant into *Bcl6*^−/−^ cells failed to repress *Id2* compared to WT Bcl6 ([Fig. 6c](#F6){ref-type="fig"}). Thus, Bcl6 directly represses *Id2* in CD4^+^ T cells.

We also asked how *Bcl6* gene copy number affected *Id2* expression. *Bcl6*^−/−^, *Bcl6*^+/−^ or WT CD4-Cre^+^ SMARTA CD4^+^ T cells were transferred into B6 mice and IL-2Rα^hi^ (T~H~1) and IL-2Rα^lo^ (T~FH~) cells were sorted following LCMV infection ([Supplementary Fig. 6b](#SD1){ref-type="supplementary-material"}). As expected, WT T~FH~ cells had reduced expression of *Id2* compared to T~H~1 cells ([Fig. 6d](#F6){ref-type="fig"}). *Id2* expression was significantly increased in IL-2Rα^lo^ Bcl6^+/−^ cells in comparison to WT cells ([Fig. 6d](#F6){ref-type="fig"}). Further, complete loss of *Bcl6* resulted in a significant upregulation of *Id2* expression in IL-2Rα^lo^ cells compared to IL-2Rα^lo^ Bcl6^+/−^ and WT cells ([Fig. 6d](#F6){ref-type="fig"}). Thus, Bcl6 inhibits *Id2* and *Bcl6* haploinsufficiency results in inappropriate Id2 expression.

Discussion {#S10}
==========

E and Id proteins are pivotal regulators of lymphocyte development and function. Here, we investigated an unexplored role for Id2 in the differentiation T~H~ cells in response to acute viral infection and show that Id2 controls the balance of T~H~1/T~FH~ by inhibiting E protein activity. Id2 and Id3 are preferentially expressed in T~H~1 and T~FH~ cells, respectively. Reduction of Id2 levels in CD4^+^ T cells results in a higher proportion of T~FH~ cells. Complete ablation of Id2 hampered T~H~1 generation, resulting in an abnormal effector population exhibiting mixed traits of T~H~1 and T~FH~ lineages. Further, Bcl6 specifically inhibits *Id2* to ensure E protein activity, driving a portion of the T~FH~ program, thus establishing Id2 as a critical enforcer of proper T~H~ differentiation.

Reduction of Id2 levels shifts the balance of T~H~1/T~FH~ cells indicating that partial expression of Id2 can inhibit enough E protein expression to maintain both helper populations while still biasing cells towards the T~FH~ lineage. Strikingly, CD4^+^ T cells that completely lack *Id2* lose the ability to form a T~H~1 effector cell population, while maintaining an intact T~FH~ population. *Id2*-deficient effector cells exhibit weak expression of T~H~1-associated genes and show simultaneous upregulation of a large portion of the T~FH~ gene program (*Cxcr5*, *Il6ra*, *Lef1* and *Tcf7*, but not *Bcl6*, *Icos* and *Pdcd1*). *Id2*-deficient cells may be unable to commit to one lineage for a number of reasons. While they adopt aspects of the T~FH~ transcriptional program, *Id2*-deficient cells also upregulate and maintain high levels of *Id3*, *Foxo1* and *Il2r*a*,* which may explain this dichotomy. Foxo1 specifically inhibits T~FH~ development^[@R38],[@R39]^. Within the first two cell divisions, expression of IL-2Rα is a key factor in driving the T~H~1 lineage decision^[@R25]^. Their expression in the absence of Id2 may counterbalance the T~FH~ gene program. Thus, Id2 and E proteins are powerful regulators of key T~FH~-associated genes and many T~H~1-associated genes, but the unusual phenotype of *Id2*-deficient effector CD4^+^ T cells demonstrates that Id2 and E proteins control gene sets that do not *per se* result in polarized differentiation of T~H~1 and T~FH~ cells.

Previous work demonstrated a role for Id3 in regulating the T~FH~ gene expression program^[@R20],[@R22],[@R24],[@R40]^. Our work further shows that specific deletion of Id3 in T~H~ cells promotes T~FH~/GC T~FH~ formation but does not impact T~H~1 differentiation following infection. Both differential expression patterns and unique binding partners are plausible explanations as to how Id2 and Id3 may control distinct T~H~ subsets. They may inhibit DNA binding of different E proteins with differing affinities and have differentially regulated binding activity and protein stability. In support of this, we observe that Id2 inhibits E47 but not Ascl2 induction of *Cxcr5*. Loss of Id2 dramatically impairs T~H~1 differentiation, but Id3-deficiency does not phenocopy Id2-deficiency, instead enhancing T~FH~ and GC T~FH~ differentiation. These observations support the hypothesis that inhibition of E proteins alters the T~H~1/T~FH~ balance: Id2 is important in the upregulation of T~H~1 genes while Id3 restrains T~FH~ differentiation.

Ascl2 has been suggested to act upstream of Bcl6 to regulate early T~FH~ differentiation^[@R22]^. However, Ascl2 is generally not detectable in naive CD4^+^ T cells^[@R41]--[@R43]^(Immgen.org), nor early T~FH~ cells^[@R26]^. Instead, Ascl2 expression is reported for fully differentiated GC T~FH~ cells in mice and humans^[@R22],[@R43]^. The high expression of E2A and HEB early after LCMV infection suggests that these E proteins, not Ascl2, direct early T~FH~ differentiation. Interestingly, Ascl2-induced expression of CXCR5 was not dampened by co-expression of Id2. GC T~FH~ have the highest levels of CXCR5 expression and Ascl2 may be important for amplifying expression at later stages of T~FH~ differentiation into GC T~FH~ cells.

There are multiple plausible models for the coordination of genes regulating the earliest stages of T~FH~ differentiation *in vivo*. Bcl6 function is critical for T~FH~ differentiation^[@R2],[@R27],[@R35]^, and can be detected as early as the second cell division *in vivo*^[@R25]^. *Tcf7* and *Lef1*, both of which are known E protein targets^[@R44]^, are epistatic to Bcl6 and promote T~FH~ differentiation by enhancing expression of Bcl6, IL-6R and ICOS and repressing *Prdm1*^[@R26],[@R45],[@R46]^. Notably, we observed increased expression of *Tcf7*, *Lef1*, and *Il6ra* in the absence of Id2, supporting the idea that E proteins such as E2A and HEB normally promote TCF-1 and LEF-1 expression. In this regard, Id2 and E proteins act upstream of Bcl6. However, our data also demonstrate that Bcl6 directly represses *Id2* expression. Altogether these data suggest that positive feedback mechanisms involving TCF-1, LEF-1, Bcl6, IL-6R, ICOS, and E proteins support T~FH~ differentiation under low Id2 conditions, and that a feedforward loop can potentially be generated by starting at any of several genes in that gene network.

The relationship between E/Id proteins, Bcl6 and CXCR5 expression is of particular interest. Ectopic expression of Bcl6 in human CD4^+^ T cells results in CXCR5 expression^[@R47]^. Coordinated expression of Bcl6 and CXCR5 in early T~FH~ cells is observed in multiple *in vivo* models^[@R25],[@R36],[@R48],[@R49]^. Yet Bcl6 does not bind to *Cxcr5*^[@R37]^, and thus must regulate its expression indirectly. One mechanism involves repression of *Cxcr5* by Blimp-1^[@R7]^. But naive T cells do not express Blimp-1, indicating that this mechanism primarily regulates later CXCR5 expression. Here, we provide a new mechanism whereby Bcl6 inhibits *Id2* expression, which yields enhanced E protein activity to drive *Cxcr5* expression.

Our data uniquely position Id2, Bcl6 and E proteins in a regulatory triad that controls the balance of T~H~1 and T~FH~ differentiation. Through inhibition of E proteins, high expression of Id2 in the T~H~1 population enforces proper development of the T~H~1 lineage. Early expression of Bcl6 in T~FH~ cells ensures repression of Id2, allowing E proteins to drive T~FH~ differentiation. Thus, dichotomous expression of Id2 is critical in ensuring the reciprocal development of T~H~1 and T~FH~ cell differentiation.

ONLINE METHODS {#S11}
==============

Mice {#S12}
----

CD4-Cre^+^ mice were from Jackson Laboratory. Mouse strains described below were bred and housed in specific pathogen--free conditions in accordance with the Institutional Animal Care and Use Guidelines of the University of California San Diego or the La Jolla Institute. Id2-YFP^[@R14]^, Id3-GFP^[@R24]^, *Id2*^fl/fl28^, *Id3*^fl/fl34^, SMARTA TCR transgenic (specific for LCMV gp66-77)^[@R50]^, *Bcl6*^fl/fl51^ CD45.1 congenic, NIP TCR transgenic (specific for LCMV NP311-325)^[@R35]^ and OT-II TCR transgenic (specific for OVA 323-339) mice were on a fully B6 background. Recipient C57BL/6J mice were either bred at UCSD or received from The Jackson Laboratory. Both male and female mice were used throughout the study, with sex and age matched T cell donors and recipients.

LCMV Infection and protein immunizations {#S13}
----------------------------------------

Recipient mice were infected by intraperitoneal injection of 2 × 10^5^ or 5 × 10^5^ plaque-forming units of LCMV-Armstrong for days 6/7 or 3 analysis, respectively. In adoptive transfer experiments of naive CD4^+^ T cells, LCMV infection was performed one day after cell transfer. A total of 20 μg of 4-Hydroxy-3-nitrophenylacetyl-OVA (NP~16~-OVA; Biosearch Technologies) was prepared in 5% alum (Aluminum potassium sulfate, Sigma) in a total volume of 20 μL and injected into each footpad.

*Toxoplasma gondii* infection and lymphocyte isolation from small intestine {#S14}
---------------------------------------------------------------------------

The ME49 strain of *T. gondii* was maintained in CBA/CaJ mice by intraperitoneal injection of 20 cysts and cysts were obtained from brain homogenates after 5--6 weeks. Mice were infected with 40 cysts of ME49 by gavage. Small intestine was harvested on day 7-post infection to analyze T~H~1 response. To isolate lamina propria lymphocytes, small intestine were cut and washed with plain RPMI-1640, and epithelial cells were removed by incubation with 5 mM EDTA and 1mM DTT for 20 min at 37 °C, followed by enzyme digestion with 0.16 U/ml liberase TL (Roche) for 30 min at 37 °C. Lymphocytes were enriched by centrifugation with 47% percoll.

Flow cytometry and histology {#S15}
----------------------------

Single-cell suspensions of spleen or draining popliteal lymph nodes were prepared by standard gentle mechanical disruption. Surface staining for flow cytometry was done with monoclonal antibodies against CD4 (RM4-5, 1:400), CD8 (53-6.7, 1:400), CD45.1 (A20, 1:400), CD25 (PC61.5, 1:400), B220 (RA3-6B2, 1:400), IgD (11-26, 1:400), PD-1 (J43, 1:400) and CD138 (eBiosciences, 1:500); PSGL-1 (2PH1, 1:800), CD138 (281-2, 1:500), Fas (Jo2, 1:400) (from BD Biosciences); SLAM (TC15-12F12.2, 1:400), CD25 (PC61, 1:400), CD4 (GK1.5, 1:400), Ly6C (AK1.4, 1:800) (BioLegend) and PNA (Vector Laboratories). Stains were done for 30 min at 4 °C in PBS supplemented with 0.5% bovine serum albumin and 0.1% sodium azide, unless specified otherwise. PE-labeled IA^b^/GP66--77 tetramer was supplied by the National Institute of Health (NIH) tetramer core facility. Single-cell suspensions were stained with tetramer at 37 °C for 2 h. CXCR5 staining was done as described^[@R52]^, using purified anti-CXCR5 (2G8; BD Pharmingen) for 1 h, followed by biotinylated anti-rat IgG (Jackson Immunoresearch), and then by PE-, PE-Cy7- or APC-labeled streptavidin (eBioscience) at 4 °C in PBS supplemented with 0.5% bovine serum albumin, 2% fetal calf serum, and 2% normal mouse serum. Intracellular staining was performed with an Alexa 647- or PE-conjugated monoclonal antibody to Bcl6 (clone K112-91; BD Pharmingen, 1:20), TCF1 (clone C63D9; Cell Signaling, 1:200), IFN-γ (clone XMG1.2; eBioscience, 1:200), T-bet (clone 4B10; eBioscience, 1:200), FoxP3 (clone FJK-16s; eBioscience, 1:200) and the Foxp3 ICS kit buffers and protocol (eBioscience). Stained cells were analyzed using LSRII, LSRFortessa or LSRFortessa X-20 (BD) and FlowJo software (TreeStar). All sorting was done on a FACS Aria (BD Biosciences). For RT-PCR analyses, early T~H~1 (IL-2Rα^+^) and T~FH~ (IL-2Rα^−^) amongst total or RV^+^ SMARTA CD4^+^ T cells were sorted 3 days after infection with LCMV. Histology was performed as previously described^[@R53]^.

ELISA {#S16}
-----

Nunc MaxiSorp plates (Thermo Fisher Scientific) were coated overnight at 4 °C with 1 μg/mL NP~23~-BSA (Biosearch Technologies) or with a 1:60 dilution of LCMV lysate (prepared from LCMV-infected BHK cells) in PBS. Plates were blocked with PBS + 0.2% Tween-20 + 1% BSA for 90 min at 25°C. After washing, mouse serum was added in a dilution series in PBS + 0.2% Tween-20 + 1% BSA and incubated for 90 min. After washing, horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (Thermo Fisher Scientific) was added at 1:5,000 in PBS + 0.2% Tween-20 + 1% BSA for 90 min at 25°C. Colorimetric detection was performed using a TMB substrate kit (Thermo Fisher Scientific). Color development was stopped after approximately 10 min with 2 N H~2~SO~4~, and absorption was measured at 450 nm.

Retroviral vectors, transductions and cell transfers {#S17}
----------------------------------------------------

shRNAmir and pMIG, Bcl6 MIG and middle domain mutant Bcl6 (K379Q) vectors were described previously^[@R27],[@R52]^. E12, E47, Ascl2, Id2 and Id3 were cloned into the pMIG or pMIA vectors, which contain an IRES-GFP or IRES-mAmetrine, respectively. Virions were produced by transfection of the PLAT-E cell line, as described previously^[@R8]^. Culture supernatants were collected 24 and 48 h after transfection, filtered through a 0.45 μm syringe filter and stored at 4°C until transduction. CD4^+^ T cells were isolated from whole splenocytes by negative selection (Stemcell Technologies) and resuspended in D-10 (DMEM + 10% fetal calf serum, supplemented with 2 mM Glutamax (Gibco) and 100 U/mL Penicillin/Streptomycin (Gibco)) with 2 ng/mL recombinant human IL-7 (Peprotech) and 50 μM β-mercaptoethanol (BME). 2 × 10^6^ cells were stimulated in 24-well plates pre-coated with 8 μg/mL anti-CD3 (17A2; BioXcell) and anti-CD28 (37.51; BioXcell). At 24 and 36 h after stimulation, cells were transduced by adding RV supernatants supplemented with 50 μM BME and 8 μg/mL polybrene (Millipore), followed by centrifugation for 90 min at 524 x *g* at 37 °C. Following each transduction, the RV-containing medium was replaced with D-10 + 50 μM BME + 10 ng/mL human IL-2. After 72 h of *in vitro* stimulation, CD4^+^ T cells were transferred into six-well plates in D-10 + 50 μM BME + 10 ng/mL human IL-2, followed by incubation for 2.5 days. One day before transfer, the culture medium was replaced with D-10 + 50 μM BME + 2 ng/mL human IL-7. Transduced cells were sorted based on reporter expression (FACSAria; BD Biosciences). Transfer of sorted cells into recipient mice was performed by intravenous injection via the retro-orbital sinus. Transferred cells were allowed to rest in host mice for 3-4 days before infection or immunization. 2 × 10^4^ or 4 × 10^5^ transduced CD4^+^ T cells were transferred into each mouse for day 6 or 3 analysis, respectively. For protein immunization, 1 × 10^5^ transduced CD4^+^ T cells were transferred into each mouse. ([Fig. 5a](#F5){ref-type="fig"}) DNA fragments encoding shRNAs targeting mouse *Tcf3* or *Cd8a* were subcloned into a custom retroviral vector containing the miR30 backbone plus the murine PGK promoter and dsRED as a reporter. 1 × 10^6^ naive *Id2*^+/+^CD4-Cre^+^ and *Id2*^fl/fl^CD4-Cre^+^ SMARTA CD4^+^ T cells were stimulated in 24-well plates pre-coated with anti-CD3 and anti-CD28 for 18 h. Following stimulation, cells were transduced by adding RV supernatants supplemented with 100 U/ml human IL-2 and 8 μg/mL polybrene, followed by centrifugation for 90 min at 2000 × *g* at 37 °C. Following transduction, cells were incubated for 3 h at 37 °C. 5×10^4^ cells were transferred into day −1 LCMV infected hosts and remaining cells were cultured *in vitro* with D-10 + 50 U/mL human IL-2 in a parallel time course to assess for knockdown efficiency.

Microarray and ChIP-seq {#S18}
-----------------------

*Id2*^+/+^ CD4-Cre^+^ and *Id2*^fl/fl^ CD4-Cre^+^ CD4^+^ T cells (pooled from 5 mice) were isolated via flow cytometry on day 7 of LCMV infection (FacsARIA, BD). For microarray analysis, RNA was extracted with TRIzol reagent, amplified and hybridized to the Affymetrix Mouse Gene 1.0 ST Array. Data were normalized and analyzed with the GenePattern software suite. E2A Bio-Chip was performed as previously described on total thymocytes from *Tcfe2a*^Bio/Bio^ *Rosa26*^BirA/BirA^ mice^[@R16],[@R54]^.

Quantitative RT-PCR and ChIP-qPCR {#S19}
---------------------------------

Total RNA from the sorted cells was extracted and reverse-transcribed, and quantitative PCR was performed using SYBR Select MasterMix (Thermo Fisher Scientific). Results were normalized to the expression of *Gapdh* transcripts. Primary GC T~FH~ were isolated from human tonsil by staining with biotin-conjugated PD-1 (J105, eBioscience) followed by isolation using Streptavidin microbeads (Miltenyi). GC T~FH~ were crosslinked with 1% formaldehyde and then quenched with 125 mM glycine. Cells were lysed in RIPA buffer (150 mM NaCl, 1% NP-40, 0.5% Na-Deoxycholate, 0.1% SDS, 50 mM Tris and 5 mM EDTA) supplemented with protease inhibitors (Thermo Fisher Scientific) and 0.5 mM PMSF followed by sonication and isolation of chromatin. Protein G Dynabeads (Life Technologies) were conjugated to antibodies specific to Bcl6 (N-3 and C-19, Santa Cruz). Normal rabbit IgG (Santa Cruz) was used as a control. Chromatin was immunoprecipitated using the conjugated beads, eluted, and reverse crosslinked using 0.3 M NaCl at 65 °C overnight. qPCR was performed on isolated DNA and sample values were given as a percentage of input. Primers are listed in [Supplementary Fig. 6c](#SD1){ref-type="supplementary-material"}.

Statistical Methods {#S20}
-------------------

Statistical tests were performed using Prism 6.0 (GraphPad). Significance was determined by unpaired Student's *t*-test with a 95% confidence interval.
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![Differential Id2 and Id3 expression defines T~H~1 and T~FH~ cell subsets\
*Id2*^YFP/+^ (**a**) or *Id3*^GFP/+^ (**b**) SMARTA CD4^+^ T cells were transferred into B6 mice and analyzed 7 days after LCMV infection. T~H~1 (SLAM^+^CXCR5^−^ or CXCR5^−^PD-1^−^), T~FH~ (SLAM^lo^CXCR5^+^ or CXCR5^+^PD-1^−^) or GC T~FH~ (CXCR5^+^PD-1^+^) cell development in the indicated SMARTA CD4^+^ T cell populations was analyzed by flow cytometry and quantified. (**c**) *Id2*^YFP/+^*Id3*^GFP/+^ SMARTA CD4^+^ T cells were transferred into B6 mice and analyzed 0, 4 or 7 days after LCMV infection. Flow cytometric analysis of Id2-YFP and Id3-GFP expression (bottom plots) in SLAM^+^CXCR5^−^ (black lines) or CXCR5^+^SLAM^lo^ (dashed lines) populations (top plots). (**d**) *Id2*^YFP/+^ reporter mice were immunized subcutaneously with phycoerythrin (PE) emulsified in TiterMax Gold Adjuvant and analyzed by histology 13 days later. Draining lymph node sections were stained with IgD (blue) and CD4 (red). Id2-YFP reporter expression is shown in green. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001 (two-tailed unpaired Student's *t* test). Data are representative of three experiments (**a--c**), each with n = 3 mice per group, or are representative of two experiments (**d**), each with n = 2 mice per group (mean ± s.e.m.).](nihms776829f1){#F1}

![Id2 knockdown results in increased T~FH~ differentiation\
SMARTA CD4^+^ T cells transduced with the indicated shRNAmir-RV were transferred into B6 mice and analyzed 6 (**a--f**) or 3 days (**g--i**) after LCMV infection. (**a--c**) T~FH~ (CXCR5^+^SLAM^lo^) and T~H~1 (SLAM^+^CXCR5^−^) differentiation was analyzed by flow cytometry (**a**) and quantified as a fraction of SMARTA CD4^+^ T cells (**b**) or total splenocytes (**c**). (**d--f**) GC T~FH~ (CXCR5^+^Bcl6^+^) differentiation was analyzed by flow cytometry (**d**) and quantified as a fraction of SMARTA CD4^+^ T cells (**e**) or total splenocytes (**f**). (**g--i**) T~FH~ (CXCR5^+^Bcl6^+^) and T~H~1 (CXCR5^−^Bcl6^−^) cell development was analyzed by flow cytometry (**g**) and quantified as a fraction of SMARTA CD4^+^ T cells (**h**) or total splenocytes (**i**). (**j--m**) OT-II CD4^+^ T cells transduced with the indicated shRNAmir-RV were transferred into *Bcl6*^fl/fl^ CD4-Cre^+^ mice and analyzed 11 days after footpad immunization with NP-OVA in alum. (**j**) Quantitation of OT-II CD4^+^ T cells. GC B cells (Fas^+^PNA^+^) (**k**) and plasma cells (CD138^+^IgD^−^) (**l**) were analyzed by flow cytometry and quantified as a fraction of B cells. (**m**) NP-specific IgG titers. The dotted line indicates NP-specific titers in naive mice. \*p\<0.05, \*\*p\<0.001, \*\*\*p\<0.0001 (two-tailed unpaired Student's *t* test). Data are pooled from four (**a--f**) five (**g--i**) or two (**j--m**) independent experiments with n=6-14 mice per group (mean ± s.e.m.).](nihms776829f2){#F2}

![Id2 is necessary for the generation of T~H~1 CD4^+^ helper cells during infection\
(**a--d**,**g**) *Id2*^+/+^ CD4-Cre^+^ (*Id2*^+/+^) or *Id2*^fl/fl^ CD4-Cre^+^ (*Id2*^−/−^) SMARTA CD4^+^ T cells were analyzed 4 (**a**,**c,d**,**g**) or 7 (**b**) days after LCMV infection. (**a**,**b**) SLAM^hi^CXCR5^−^ (green), SLAM^mid^CXCR5^mid^ (purple) and SLAM^lo^CXCR5^+^ (blue) cells were analyzed (left panels) and quantified as a frequency of SMARTA CD4^+^ T cells (middle panels) and total cell numbers (right panels). PSGL-1 and Ly6C (**c**) and IL-2Rα or Bcl6 (**d**) expression on the indicated subsets, histogram color (**d**) corresponds to the gates drawn in (**a**). (**e**,**f**) *Id2*^+/+^ or *Id2*^−/−^ cells were transferred into *Bcl6*^fl/fl^ CD4-Cre^+^ mice and analyzed 8 (**e**) days after LCMV infection. (**e**) Analysis and quantification of GC B cells (Fas^+^PNA^+^) or plasma cells (CD138^+^IgD^−^) as a normalized frequency of B cells. (**f**) LCMV-specific IgG titers at the indicated time points. (**g**) viSNE analysis of total splenic CD4^+^ T cells (left panel) or SMARTA CD4^+^ T cells (right panels), with visualization of SLAM and Bcl6 expression by color gradient. (**h**) *Id2*^+/+^ CD4-Cre^+^ or *Id2*^fl/fl^ CD4-Cre^+^ mice were infected with *T. gondii* and analyzed 7 days after infection. Analysis and quantification of IFNγ, T-bet and Foxp3 expression by lamina propria CD4^+^ T cells. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001 (two-tailed unpaired Student's *t* test). Data are representative of two (**f,h**) or three (**a--d,g**) experiments, each with n= 5--10 mice per group, or are pooled from two (**e**) independent experiments each with n= 10 mice per group (mean ± s.e.m.)](nihms776829f3){#F3}

![Increased E2A binding in the absence of Id2 regulates expression of key T helper genes\
*Id2*^+/+^ CD4-Cre^+^ (*Id2*^+/+^) or *Id2*^fl/fl^ CD4-Cre^+^ (*Id2*^−/−^) SMARTA CD4^+^ T cells were transferred into B6 hosts and infected with LCMV. (**a**) Microarray analysis was performed on the indicated T~H~1 and T~FH~ populations sorted 7 days after LCMV infection. (**b** and **c**) Comparisons between the indicated populations are shown as expression-by-expression plots with FC ≥1.4, CV ≤ 0.10 and expression ≥40. (**d**) Expression of putative E2A-target genes identified by ChIP-seq between *Id2*^+/+^ T~H~1 (purple) and *Id2*^−/−^ T~H~1 (grey). White bars indicate genes not significantly differentially regulated. (**e-h**) Volcano plots for the indicated data sets. (**e**) Differentially regulated *Id2*^+/+^ T~H~1 genes from *Id2*^+/+^ T~H~1 vs *Id2*^+/+^ T~FH~ mean-class expression (MCE) plot (**b**). (**f**) Differentially regulated *Id2*^+/+^ T~H~1 genes from *Id2*^+/+^ T~H~1 vs *Id2*^−/−^ T~H~1 MCE plot (**c**). (**g**) Differentially regulated *Id2*^+/+^ T~FH~ genes from *Id2*^+/+^ T~FH~ vs *Id2*^+/+^ T~H~1 MCE plot (**b**). (**h**) Differentially regulated *Id2*^−/−^ T~H~1 genes from *Id2*^−/−^ T~H~1 vs *Id2*^+/+^ T~H~1 MCE plot (**c**). (**i**) Comparisons between *Id2*^+/+^ and *Id2*^−/−^ T~FH~ are shown as expression-by-expression plots with FC ≥1.4, CV ≤0.10 and expression ≥40. (**j**) Frequency of differentially regulated genes (FC ≥1.4) between *Id2*^+/+^ T~H~1 and *Id2*^−/−^ T~H~1 populations, which are also E2A targets as indicated by E2A ChIP-seq. Black bar indicates the background frequency of E2A targets. Data are representative of 2 independent experiments each with n= 5 mice per group.](nihms776829f4){#F4}

![E proteins drive CXCR5 expression and inhibit T~H~1 formation\
(**a**) *Id2*^+/+^ CD4-Cre^+^ (*Id2*^+/+^) or *Id2*^fl/fl^ CD4-Cre^+^ (*Id2*^−/−^) SMARTA CD4^+^ T cells were transduced with the indicated shRNAmir-RV, transferred into B6 mice and analyzed 7 days after LCMV infection. T~H~1 cells were analyzed by flow cytometry and quantified as a fraction of transduced SMARTA CD4^+^ T cells. (**b**) CXCR5 expression in GFP^+^ CD4^+^ T cells and pooled quantitation. (**c**) Quantitation of CXCR5 expression by RV^+^ SMARTA T~FH~ (CXCR5^+^Bcl6^+^) cells 3 days after LCMV. (**d--k**) RV transduced NIP CD4^+^ T cells were transferred into B6 mice and analyzed 3 (**d--g**) or 6 days (**h--k**) after LCMV infection. (**d--g**) T~FH~ (CXCR5^+^Bcl6^+^) and T~H~1 (CXCR5^−^Bcl6^−^) differentiation was analyzed by flow cytometry (**d**) and quantified as a fraction of NIP CD4^+^ T cells (**f**) or total splenocytes (**g**). (**e**) Quantitation of CXCR5 expression in NIP T~FH~ (CXCR5^+^Bcl6^+^) cells. (**h--k**) T~H~1 (PSGL-1^+^CXCR5^−^), T~FH~ (CXCR5^+^PSGL-1^+^) and GC T~FH~ (CXCR5^+^PSGL-1^−^) cell development was analyzed by flow cytometry (**h**) and quantified as a fraction of NIP CD4^+^ T cells (**j**) or total splenocytes (**k**). (**I**) Quantitation of CXCR5 expression in NIP T~FH~ (CXCR5^+^SLAM^lo^) cells. (**l**) CXCR5 expression by GFP^+^Ame^+^ CD4^+^ T cells and quantitation. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001(two-tailed unpaired (a--k) or paired (l) Student's *t* test). Data are representative of two (**a,c**), three (**d,e**) or four (**h,i**) independent experiments or pooled from two (**f,g,j,k**), four (**l**) or nine (**b**) individual experiments each with n= 3-8 mice per group (mean ± s.e.m.).](nihms776829f5){#F5}

![Bcl6 inhibits *Id2* expression\
(**a**) BCL6, H3K27Ac, H3K4me1 and H3K4me3 density tracks of *ID2* in human GC T~FH~ cells. Arrows above the BCL6 tracks indicate primers used in ChIP-qPCR analysis. Sequence conservation with mouse is shown at the bottom. (**b**) PD-1^hi^ GC T~FH~ cells were isolated from human tonsil cells, chromatin was prepared and ChIP was performed for BCL6 at the indicated loci. (**c**) *Bcl6*^fl/fl^ CD4-Cre^+^ SMARTA CD4^+^ T cells transduced with the indicated vectors were transferred into B6 mice. IL-2Rα^+^ SMARTA CD4^+^ T cells were sorted 3 days after LCMV infection and *Id2* expression was tested by qRT-PCR. (**d**) WT (*Bcl6*^+/+^), *Bcl6*^fl/WT^ CD4-Cre^+^ (*Bcl6*^+/−^), *Bcl6*^fl/fl^ CD4-Cre^+^ (*Bcl6*^−/−^) SMARTA CD4^+^ T cells were transferred into B6 mice. IL-2Rα^+^ or IL-2Rα^−^ SMARTA cells were sorted and *Id2* expression was tested by qRT-PCR. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.0001 (two-tailed unpaired Student's *t* test). Data are pooled from two (**c,d**) or four (**b**) independent experiments, with n= 5 mice per group (**b**) (mean ± s.e.m.). For c and d, 3 mice were pooled to create a data point.](nihms776829f6){#F6}
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